TxCell: Presentation of New Transplantation CAR-Treg Data at ESOT 2017
13 September 2017 - 4:45PM
Business Wire
Regulatory News:
TxCell SA (Paris:TXCL) (FR0010127662 – TXCL), a
biotechnology company developing innovative, personalized cellular
immunotherapies using regulatory T cells (Treg) to treat severe
inflammatory and autoimmune diseases as well as transplant
rejection, today announces that new preclinical data will be
presented at the 18th Congress of the European Society for Organ
Transplantation (ESOT) to be held in Barcelona from Sept 24-27,
2017.
An oral presentation entitled ‘Alloantigen-specific regulatory
T-cells generated with a chimeric antigen receptor’ will be made on
September 26, 2017 at 11.50 am CEST by Megan Levings, PhD,
Professor, Department of Surgery, University of British Columbia
(UBC) and Head, Childhood Diseases Research Theme, BC Children's
Hospital in Vancouver, Canada. TxCell and UBC have been
collaborating on the development of a CAR-Treg-based cellular
immunotherapy for the prevention of graft rejection in the context
of solid organ transplantation since October 2016.
Further details will be communicated in due time. The full
program is available on the conference website
http://esot2017.esot.org/.
About TxCell – www.txcell.com
TxCell is a biotechnology company that develops platforms for
innovative, personalized T cell immunotherapies for the treatment
of severe inflammatory and autoimmune diseases with high unmet
medical need. TxCell is targeting a range of autoimmune diseases
(both T-cell and B-cell-mediated) including Crohn’s disease, lupus
nephritis, bullous pemphigoid and multiple sclerosis, as well as
transplant rejection.
TxCell is the only clinical-stage cellular therapy company fully
dedicated to the science of regulatory T lymphocytes (Tregs). Tregs
are a recently discovered T cell population for which
anti-inflammatory properties have been demonstrated. Contrary to
conventional approaches based on non-specific polyclonal Tregs,
TxCell is exclusively developing antigen-specific Tregs. This
antigen specificity may either come from genetic modifications with
Chimeric Antigen Receptor (CAR) or from pre-existing Treg cell
T-Cell Receptor (TCR). TxCell is developing two proprietary
technology platforms, ENTrIA, which is composed of
genetically-engineered Tregs, and ASTrIA, which is composed of
non-modified naturally antigen-specific Tregs.
Based in Sophia-Antipolis, France, TxCell is listed on Euronext
Paris and currently has 46 employees.
Next events
Scientific and medical
conferences
Sept 20-21 Phacilitate Leaders Forum Europe Berlin
(DE) Sept 24-27 ESOT 2017 (European Society for Organ
Transplantation) Barcelona (SP) Sept 26 Journée « Bioproduction des
immunothérapies en France » Paris (FR) Oct 9-11 Final conference on
the COST ‘A FACTT’ project Barcelona (SP) Oct 17-20 ESGCT 2017
(European Society of Gene & Cell Therapy) Berlin (DE)
Financial and business
conferences
Sept 26-27 Annual Biotech in Europe Investor Forum (Sachs
Associates) Basel (CH) Oct 4-5 Large & Midcap Event Paris Paris
(FR) Oct 4-5 Cell & Gene Meeting on the Mesa La Jolla (US) Nov
6-9 BIO-Europe Berlin (DE) Nov 9 5th Annual European Advanced
Therapies Investor Day London (UK) Nov 14 Inv€$tival Showcase
London (UK) Nov 15-16 Jefferies 2017 Global Healthcare Conference
London (UK) Nov 23-24 Actionaria Paris (FR)
Forward-Looking Statements
This press release contains certain forward-looking statements
relating to the business of TxCell, which shall not be considered
per se as historical facts, including TxCell’s ability to develop,
market, commercialize and achieve market acceptance for specific
products, estimates for future performance and estimates regarding
anticipated operating losses, future revenues, capital
requirements, needs for additional financing. In addition, even if
the actual results or development of TxCell are consistent with the
forward-looking statements contained in this press release, those
results or developments of TxCell may not be indicative of their in
the future.
In some cases, you can identify forward-looking statements by
words such as "could," "should," "may," "expects," "anticipates,"
"believes," "intends," "estimates," "aims," "targets," or similar
words. Although the management of TxCell believes that these
forward-looking statements are reasonably made, they are based
largely on the current expectations of TxCell as of the date of
this press release and are subject to a number of known and unknown
risks and uncertainties and other factors that may cause actual
results, performance or achievements to be materially different
from any future results, performance or achievement expressed or
implied by these forward-looking statements. In particular, the
expectations of TxCell could be affected by, among other things,
uncertainties involved in the development of the Company’s
products, which may not succeed, or in the delivery of TxCell’s
products marketing authorizations by the relevant regulatory
authorities and, in general, any factor that could affects TxCell
capacity to commercialize the products it develops, as well as, any
other risk and uncertainties developed or identified in any public
documents filed by TxCell with the AMF, included those listed in
chapter 4 “Risk factors” of the 2016 document de référence
(registration document) approved by the AMF on April 26, 2017 under
number R.17-024. In light of these risks and uncertainties, there
can be no assurance that the forward-looking statements made in
this press release will in fact be realized. Notwithstanding the
compliance with article 223-1 of the General Regulation of the AMF
(the information disclosed must be “accurate, precise and fairly
presented”), TxCell is providing the information in these materials
as of this press release, and disclaims any intention or obligation
to publicly update or revise any forward-looking statements,
whether as a result of new information, future events, or
otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170913005845/en/
TxCellCaroline CourmeIR & Communication DirectorTel:
+33(0) 4 97 21 83 00caroline.courme@txcell.comorImage Box –
Press relationsNeil Hunter / Michelle BoxallTel: +44(0) 20 8943
4685neil.hunter@imageboxpr.co.ukmichelle.boxall@imageboxpr.co.ukorNewCap
– Investor relationsJulien Perez / Mathilde BohinTel: +33 (0)1
44 71 98 52txcell@newcap.eu